Ysios BioFund I

Overview

Ysios BioFund I is a prominent Spanish venture capital fund managed by Ysios Capital, focusing on investments in the biotechnology sector. The fund was established in 2008 with a total capital of €69 million and has made nine investments to date. Its portfolio includes companies such as Inbiomotion, Medlumics, AM-Pharma BV, STAT Diagnostica, Sabirmedical, Cardoz, Endosense, Biovex (now part of Amgen), and Cellerix (now Tigenix NV). The fund primarily invests in early-stage companies specializing in pharmaceuticals, diagnostics, and medical devices. It seeks to acquire temporary equity stakes in companies operating in the health sciences and biotechnology sectors with international prospects, aiming to accelerate growth and facilitate entry into international markets. The investment size ranges from €500,000 to €4 million, targeting both young companies and those in the development and consolidation phases, including spin-offs from pharmaceutical companies. Ysios BioFund I has achieved notable exits, including the sale of BioVex to Amgen for $1 billion and the acquisition of Endosense by St. Jude Medical for up to 325 million CHF. These successful exits have provided early returns to investors, well ahead of the typical 5-7 years associated with venture capital investments. The fund continues to actively seek new investment opportunities in the biotechnology sector, contributing to the growth and innovation of the industry.

Investment Focus

• Companies specializing in biotechnology, medical devices, pharmaceuticals, diagnostics, and healthcare sectors with international growth potential.

Portfolio Companies